Clinical Practice

Join/Renew Contact ONS Terms of Use FAQ

HOME

CNE Central

Biologics and Molecular Targeted Therapies Home

Untitled Document

ONS Profile

Login

Username:

Password:

Forgot Password

Edit Profile
Log Off

Biologics and Molecular Targeted Therapies/Immunotherapy/Nano Technology Clinical Resource Area - Education

Biological and Molecular Targeted Therapies in Cancer Treatment
This slide show was developed by Oncology Education Services (OES) with a grant from Genentech BioOncology.It reviews the mechanisms of action of biological and molecular targeted therapies, its use in cancer, side effects and future directions.

Chemotherapy and Biotherapy Update
2.3 Contact Hours
Update your clinical knowledge of chemotherapy administration with this new online course. Material covered includes practices issues on error prevention and safe handling, case studies on symptom management, and information on newly approved medications.

Cytokines & B-Cell Malignancies: Maximizing Therapeutic Outcomes
2.6 Contact Hours
Expires: 1/30/09
This program is sponsored by an educational grant from Berlex Oncology, Inc.
This monograph is an independent study for oncology nurses interested in learning about the phenomena of antibody-dependent cell-mediated cytotoxicity in the treatment of B-cell malignancies. The monograph will summarize treatment options and their limitations for follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia as well as summarize data on mechanisms to delay disease relapse.

Clinical Breakthroughs in EGFR Inhibition: Applying the Science to Your Clinical Practice
2.1 Contact Hours
The webcast is supported by an educational grant from Amgen Inc.
What are the hottest new clinical developments in targeted therapies? This webcast takes a fascinating look at EGFR inhibition, including an illustrated explanation of cellular changes, a clinical review of promising new treatments, and a comprehensive discussion of side effects and their management. Participants will gain a clear understanding of how side effects correlate with treatment progression and with proven strategies to successfully manage the side effects of EGFR inhibitors.

ONS Chemotherapy and Biotherapy Trainer Course
13.5 Contact Hours
In an effort to encourage consistency in practice in the area of chemotherapy administration, ONS has developed a Chemotherapy and Biotherapy Course that is presented throughout the U.S. Learn more about the courses at the link above. Visit the Chemotherapy Course Virtual Community for a list of trainers, cities, and dates. Once you find a course you'd like to attend, contact the trainer directly.

ONS Safe Handling of Hazardous Drugs Online Course
10.3 Contact Hours
Safe Handling of Hazardous Drugs is an informative course providing the quality instruction you expect from ONS in a new, convenient format. The classes are faculty-mediated programs, allowing students to interact directly with the faculty through e-mail and chat forums. Working along with the text, students will engage in self-paced reading assignments, activities, and learning opportunities. Students will interact with faculty through e-mails, chat forums, and ongoing evaluation of assignments. The student forums will provide opportunities to share expertise with colleagues. Learn more about the course at the link above.
Visit the CNE Central area of www.ons.org for more details.

Renal Cell Carcinoma - Today’s Targeted Therapies Improving Tomorrow’s Outcomes
This newsletter is based upon a symposium which was offered through Meniscus Educational Institute at the 30th Annual ONS Congress. This program outlines the care of renal cell carcinoma including targeted therapy and the use of interleukin-2 and nursing management of side effects of therapy.
CE is no longer available with this program.

ONS Congress Abstracts

2007

1883

IMPLEMENTING AN ANTINEOPLASTIC HYPERSENSITIVITY PROTOCOL: A NURSING PERSPECTIVE.

2010

A NURSE CAN SAFELY DELIVER RITUXIMAB OVER 90 MINUTES.

2059

PRECAUTIONS, IMPLICATIONS AND CONTRAINDICATIONS: USING EVIDENCE TO ESTABLISH A NURSING PROTOCOL FOR A RECOMBINANT POXVIRUS (VACCINIA/FOWLPOX) BASED VACCINE PROGRAM.

2165

INCIDENCE AND NURSING MANAGEMENT OF HAND FOOT SKIN REACTION IN PATIENTS TREATED WITH ORAL TYROSINE KINASE INHIBITORS FOR METASTATIC RENAL CELL CARCINOMA.

2228

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITORS (EGFR-TFI): THE NURSE’S ROLE IN MANAGEMENT OF PATIENTS RECEIVING MOLECULAR TARGETED THERAPIES.

2235

EFFICACY OF GABAPENTIN ON PRURITUS INDUCED BY INTERLEUKIN-2 (IL-2) TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA AND MELANOMA.

2262

HPV VACCINE—AN EVALUATION OF THE EVIDENCE SUPPORTING ITS USE.

2407

ONS/NBNA HPV AND CERVICAL CANCER INITIATIVE.

2006

Skin Reactions Associated With Oral Revlimid (Lenalidomide) in AL Amyloidosis (ALA); Patient Teaching Encouraging Prompt Reporting, and Clinical Assessment and Management of Skin Reactions Can Impact Patient Outcomes

Bevacizumab: A New Treatment for Non-Small Cell Lung Cancer?

Nursing Implications Regarding the Management of Side Effects in a Phase I Study Using Gefitinib With Rapamycin